Kornimate/medical-research-clean huggingface dataset:
safety and efficacy of body-mapping tank top equipped with biofeedback system for adolescent with early scoliosis

Conditions: Adolescent Idiopathic Scoliosis

Summary: adolescent idiopathic scoliosis (ais) is a prevalent disease that caused a lateral curvature on spine. spine curvature increases in youths as puberty progresses. the recommended treatment for ais is different depends on the spine deformity condition. for mild scoliosis (cobb's angle ≤ 20°), only periodic observation is suggested. for scoliosis cases that the cobb's angle ≤ 40°, a rigid brace treatment is recommended. a rigid brace that made by rigid plastic material restrict nearly all movements of the wearers, which caused irritation. flexible brace is an alternative option, however, the efficiency of such treatment is questionable in terms of controlling the spine curvature progression. biofeedback has proven to be effective for a number of physical, psychological and psychophysical problems. the basic aim of biofeedback therapy is to support a patient in realizing his/her self-ability to control specific psychophysiological processes. in this study, a biofeedback embedded tank-top with a specialized design for adolescents as a treatment option for ais patients by monitoring the daily posture of the wearers.

this project aims to combine the clinical experience with textiles and biofeedback mechanism to research and develop a biofeedback embedded tank-top for ais. as a result, this will reduce the future likelihood of brace wear or surgery. in this study, the eligible subjects will be given tailor-made biofeedback tank-top to wear it 8 hours daily. monitor, observation and additional posture training sessions will be provided during the 6 months wearing period. the effectiveness of the biofeedback tank-top will be evaluated by pre-and post- treatment ultrasonic imaging device (for measuring the angle of the spine), electromyography muscle signal assessment and clinical photographs assessment.

Eligibility criteria:
inclusion criteria: * aged 10 to 13 years * diagnosis of ais in early stage * primary cobb angle between 10 -20 degrees * pre-menarche or post- menarche by no more than 1 year * ability to read and understand english or chinese * at high risk for curve progression * skeletally immature (risser grade 0,1 or 2) * physical and mental ability to adhere to functional intimate apparel protocol exclusion criteria: * contraindications for x-ray exposure * diagnosis of other musculoskeletal or developmental illness that might be responsible for the spinal curvature * history of previous surgical or orthotic treatment for ais * contraindications for pulmonary and/ or exercise tests * psychiatric disorders * recent trauma * recent traumatic (emotional) event
capecitabine and pseudomonas aeruginosa combination in metastatic breast cancer (mbc)

Conditions: Metastatic Breast Cancer

Summary: the progression free survival could be prolonged adding pseudomonas aeruginosa to monotherapy capecitabine.

the efficacy of the combination is much better than monotherapy

Eligibility criteria:
inclusion criteria: 1. female between 18 and 70 years old 2. patients with histologic proved metastatic breast cancer, unsuitable to be treated locally. 3. patients with her-2 negative breast cancer(her-2 negative or one plus by ihc test , if her-2 two plus by ihc,fish result should be negative) 4. disease progression after anthracycline and/or taxane regimen therapy and candidate for capecitabine monotherapy 5. patients previously treated by capecitabine containing regimen should response to the chemotherapy containing capecitabine and progressed at least 4 months after the last capecitabine treatment 6. karnofsky score more than 70；ecog 0\~2； 7. normal functions with heart, liver,renal and bone marrow 8. wbc≥4×109/l；hb≥90 g/l；plt≥100×109/l 9. got icf before enrollment exclusion criteria: 1. pregnant or breast-feeding women or positive serum pregnancy test 2. uncontrolled brain metastases. patients with brain metastases must be locally treated and the disease must be stable for at least one month at the time of enrolling 3. participation in any investigational drug study within 4 weeks preceding treatment start. 4. concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin or a contralateral breast cancer. 5. serious uncontrolled intercurrent infections 6. poor compliance
diagnostics in the leg ulcer pathway

Conditions: Venous Leg Ulcer

Summary: this project aims to investigate 'the minimum diagnostic requirements for patients presenting to primary care with suspected venous ulcers.' in order to do this, the investigators intend to run a series of questionnaires with primary care services, vascular science services, and perform some cost effectiveness modelling on running diagnostic services in primary care and in secondary care settings. a one off questionnaire, designed in qualtrics, will be sent out to primary care practitioners via social media and email contacts. this will be aimed at establishing their current role and any guidelines they follow with regards to the diagnosis and management of venous leg ulcers in primary care, and to determine their opinion of what this patient pathway should involve. a delphi consensus will be carried out amongst vascular scientists across the uk to determine current and streamline future practice in diagnostics for patients with venous leg ulcers. the consensus will be achieved when there is ≥ 70% agreement. cost effectiveness modelling will be carried out on two different scenarios of managing this cohort of patients, one in primary care and one in secondary care settings. descriptive statistics will be performed on the results.

the main objective of this project is to determine the role/position of diagnostic imaging in the patient journey for a patient with active or healed ulceration. 1. to determine the current practice in primary care for venous leg ulcer management and availability of services to onward referral. 2. to determine the current practice for diagnosis and management of suspected venous leg ulcers in vascular scientist departments across the uk 3. to establish what the minimum diagnostics should be for this cohort of patients including what scans should be performed and can a set criterion be applied to this cohort of patients. 4. to determine the cost effectiveness of implementing this in both primary and secondary care settings.

Eligibility criteria:
inclusion criteria: * primary care practitioners working in the uk will be recruited for the primary care questionnaire. * vascular scientists working in a secondary care hospital in the uk will be recruited for the online delphi consensus. exclusion criteria: * participants not meeting the inclusion criteria.
total intravenous anesthesia and recurrence free survival

Conditions: Esophageal Cancer

Summary: the investigators propose to compare recurrence-free survival in patients having potentially curative (stages 1-3) surgery for esophageal cancer who will be randomly assigned to propofol-based total intravenous anesthesia or sevoflurane-based balanced general anesthesia.

the investigators will test the primary hypothesis that recurrence-free survival after esophageal cancer surgery is longer in patients randomized to propofol-based total intravenous anesthesia than to volatile sevoflurane anesthesia. the investigators will test the secondary hypotheses that propofol-based total intravenous anesthesia: 1) speeds discharge from the icu; 2) speeds discharge from the hospital; and, 3) improves the quality of recovery, as assessed by qor-15 on postoperative day 2.

Eligibility criteria:
inclusion criteria: * primary esophageal cancer without known extension beyond the esophagus. (i.e. believed to be tumor stage 1-3). * scheduled for potentially curative esophageal cancer surgery. * written informed consent, including willingness to be randomized to intravenous versus volatile anesthesia. exclusion criteria: * previous surgery for esophageal cancer (except diagnostic biopsies) age \ 85 years old. * asa physical status ≥4. * any contraindication to propofol or sevoflurane. * other cancer not believed by the attending surgeon to be in long-term remission. * systemic disease believed by the attending surgeon to present ≥25% two- year mortality.
the metabolomics of intestinal polyps of different pathological types and tcm syndromes and tcm constitution types

Conditions: Intestinal Polyps

Summary: the aim of this study is to confirm the tcm syndrome types and tcm constitution classifications of the patients with intestinal polyps via on-site epidemiological survey, to analyze metabolomics of the serum samples of intestinal polyps and healthy volunteers, and to study the metabolomics differences of the two populations and the metabolomics variations of the patients with intestinal polyps of pre-polypectomy and post-polypectomy. finally, this study is to investigate the serum metabolomics variations of patients with intestinal polyps of pre-polypectomy and post-polypectomy and the relationship with their tcm syndrome types and tcm constitution classifications, to determine the correlation among pathology, tcm constitution, tcm syndrome types and the metabonomics variations of patients with intestinal polyps.


Eligibility criteria:
inclusion criteria: 1. age 20 to 80,all genders; 2. intestinal polyps were found by colonoscopy; 3. the patients are scheduled for polypectomy; 4. preoperative examinations were completed; 5. performance status 0-1; 6. diet has well controlled prior to the operation; 7. patients or their statutory agent have signed the informed consent forms. exclusion criteria: 1. the patient has not diagnosed by colonoscopy; 2. the patient has surgical contraindication; 3. patients in pregnant or lactational period ; 4. psychopath; 5. the patient is in drug trial.

Keywords: metabolomics intestinal polyps tcm syndromes tcm constitution types
cmv-associated immunomodulation in renal transplant patients

Conditions: Kidney Transplantation

Summary: cytomegalovirus (cmv) infection has been associated with an increased risk of bacterial, fungal and viral infections in solid organ transplant recipients. the purpose of this study to evaluate if the occurrence of cmv viremia modify the ability to develop optimal immune responses against other pathogens in kidney transplant recipients (heterologous immunity). the objective of this project is to identify the immune pathways affected by cmv in the context of immunosuppression associated with kidney transplantation.

cytomegalovirus (cmv) infection remains one of the most frequent and problematic complications of solid organ transplantation. several epidemiological studies have shown an association between cmv infection and the occurrence of severe bacterial or fungal infections. however, the mechanisms by which cmv increases the risk of heterologous infection are still poorly understood. several data support a direct or indirect immunomodulatory effect of cmv. indeed, in healthy subjects, cmv seropositivity has a strong phenotypic and functional impact on adaptive immunity while in solid organ transplant patients, a decrease in the innate response to various antigenic stimuli has been observed during cmv viremia. the hypothesis of the study is that the occurrence of cmv viremia reduces the ability to develop optimal immune responses against other targeted pathogens in kidney transplant recipients (heterologous immunity). the objective of this project is to identify the immune pathways affected by cmv in the context of immunosuppression associated with kidney transplantation.

Eligibility criteria:
inclusion criteria: 1. st cohort : * age \> 18 years * patients with end-stage renal failure programmed for kidney transplantation with a live donor 2. nd cohort : * age \> 18 years * kidney transplant recipient with cmv viremia exclusion criteria: - patients under guardianship, curatorship, legal protection. for patients with end-stage renal failure scheduled to receive a kidney transplant from a living donor : * patients with an active viral (other than cmv), bacterial or fungal infection at the time of inclusion * patients receiving a desensitization protocol (abo or anti-hla)

Keywords: kidney transplant solid organ transplantation cytomegalovirus infection immunomodulatory effect of cytomegalovirus infection heterologous infection
treatment of breast lift/reduction scars

Conditions: Scars

Summary: laser and light treatment for surgical scars following breast lifts/reductions

the purpose of the study is to demonstrate effectiveness of laser and light therapy for the treatment of surgical scars following breast lifts/reductions.

Eligibility criteria:
inclusion criteria: 1. healthy female subjects between 25 to 60 years of age inclusive 2. fitzpatrick skin type i-iv 3. subjects with post-surgical breast lift/reduction scar 4. a maximum of 8-10 weeks since surgery 5. healed surgery wound in the treatment area 6. willing to have photographs taken of the treatment area 7. can read, understand and sign informed consent form (english only) 8. has indicated willingness to participate in the study by signing an informed consent form 9. agrees to adhere to the treatment and follow-up schedule and post treatment care instructions exclusion criteria: 1. fitzpatrick skin type v-vi 2. breast reconstruction with radiation treatment 3. is pregnant and/or lactating 4. has tattoos, dysplastic nevi in the treatment area 5. history or current photosensitivity 6. history or current use of medication with photosensitizing properties within past 6 months 7. history or current of chronic reoccurring skin disease or disorder affecting treatment area 8. history or current cancer of any type 9. has hormonal disorder 10. has signs of actinic bronzing 11. has open lacerations, and abrasions on the treatment area 12. history of keloid formation, or hypertrophic scar formation, or poor wound healing 13. history of bleeding disorder, or is currently taking anticoagulation medications 14. has significant concurrent illnesses (controlled or uncontrolled), such as diabetes, lupus, epilepsy, or cardiac disorders, which might be aggravated as a result of treatment 15. has participated in any clinical trial involving an investigational drug, device or cosmetic product or procedure within the past 30 days 16. the investigator feels that for any reason the subject is not eligible to participate in the study.

Keywords: breast reduction scars breast lift scars
improving diet and exercise in acute lymphoblastic leukemia (ideal weight in all)

Conditions: B Precursor Type Acute Leukemia

Summary: this study tests the ability of a focused dietary, exercise, and activity intervention to reduce fat gain during induction therapy for childhood acute lymphoblastic leukemia to improve disease response and reduce toxicity.

in our previous study, we have observed that: 1) nearly half all patients are overweight or obese at diagnosis, 2) all patients, regardless of starting weight, gain significant fat mass over the first month of therapy (on average 20-30%), and 3) obesity at the time of diagnosis is associated with a higher likelihood of poor response to chemotherapy as evidenced by persistent leukemia (minimal residual disease) after induction therapy. together, these data show that body fat is a significant risk factor for all treatment failure, and that its negative effects are evident within the first month of treatment. recent laboratory and clinical data illustrates the ability of diet restriction and physical activity to improve chemotherapy efficacy, reduce treatment-related toxicities and better overall quality of life. given the importance of successful induction therapy for all in predicting long term survival and the negative role of obesity on treatment success, this study tests a complete personalized dietary and exercise intervention for pre-adolescents, adolescents, and young adults newly diagnosed with b-precursor all ("pre-b all") that aims to reduce fat gained during induction therapy and thereby improve treatment response, toxicity rates, and quality of life.

Eligibility criteria:
inclusion criteria: * greater than or equal to 10 years of age and less than or equal to 21 years of age at time of diagnosis * have a new diagnosis of untreated nci/rome high risk b-precursor all (hr-all) * are beginning treatment on- or as per- a children's cancer group/children's oncology group (ccg-cog) protocol with a 4-drug induction including vincristine, daunorubicin (or doxorubicin), asparaginase, and at least 14 days of glucocorticoid steroids exclusion criteria: * have a diagnosis of down syndrome (trisomy 21) or any genetic disease associated with abnormal body composition * be underweight or "at risk for underweight" with moderate weight loss, defined as a starting body mass index (bmi) \ 20 years of age, defined as an absolute bmi \< 18.5) * have pre-existing abnormal intestinal function (e.g. protein-wasting enteropathy, fat malabsorption) * be unable to comply with the recommended diet or activity interventions (as determined by study or treatment team) * have a history of prior chemotherapy or radiation for other cancers * be unable to complete the necessary radiology examinations with fully interpretable data (e.g. hip replacement and metal prostheses preclude evaluation by dxa) * be pregnant (to be confirmed by urine or serum pregnancy test as per institutional routine care for chemotherapy and radiology exams)
fatigue in dystonia (a single session, questionnaire-based study of fatigue in dystonia)

Conditions: Dystonia

Summary: the purpose of this study is to determine how common fatigue and sleepiness are in patients with dystonia.

the purpose of the study is to determine the prevalence of fatigue in patients with dystonia. there are many factors which may impact fatigue but perhaps the most important of these is sleep. it is therefore critical that we collect data on sleep habits and sleepiness to help interpret our data on fatigue. we will be using the epworth sleepiness scale to assess daytime somnolence and the parkinson's disease sleep scale to assess the presence or absence of common sleep disorders affecting patients with movement disorders along with the multidimensional fatigue inventory and the fatigue severity scale.

Eligibility criteria:
inclusion criteria: diagnosis of dystonia * informed consent to be contacted about research exclusion criteria: * none
quantitative ultrasound assessment of gastric volume in pregnant women at term

Conditions: Respiratory Aspiration; Pregnancy

Summary: solid food or fluid residue in the stomach is always a major concern when patients need medical procedures under sedation or general anesthesia, due to the high risk of pulmonary aspiration of the stomach contents. this is especially important in emergency procedures, when a fasting period is not observed. the aspiration of the stomach contents into one's lungs can lead to serious complications (such as severe respiratory failure). information from a bedside ultrasound assessment of the stomach may be a very useful tool to decide whether or not it's safe to proceed, cancel or delay a surgical procedure. the investigotrs hypothesize that a mathematical model can be constructed to predict clear fluid volume in the stomach of non-labouring pregnant patients, as it has been developed in healthy adult volunteers.

food residue in the stomach of patients scheduled to have surgery is considered a major risk factor for pulmonary aspiration of gastric contents. the resulting respiratory compromise after aspiration is associated with significant morbidity and mortality. the risk of pulmonary aspiration is especially important in pregnant women, as they may often require surgery without having observed appropriate fasting. a bedside ultrasound assessment of the status of the gastric content would be of great value for the clinician. this technique has recently been shown very promising in non-pregnant patients and it is important to study its feasibility in the pregnant population. in this study, patients fast overnight and are randomized to the following groups: empty, or various volumes of fluid (50, 100, 200, 300 or 400ml of apple juice before scanning). their gastric contents are then assessed by an anesthesiologist, using ultrasound. the investigators aim to evaluate a standardized quantitative ultrasound assessment of gastric volume in non-labouring pregnant women.

Eligibility criteria:
inclusion criteria: * volunteer non-labouring pregnant women at term (≥ 36 weeks)- * 18 years or older * asa physical status i-iii * 50-120 kg of weight * 150 cm of height or taller * ability to understand the rationale of the study assessments and to provide signed informed consent * written informed consent exclusion criteria: * known pre-existing abnormal anatomy of the upper gastrointestinal tract * history of upper gi tract surgical procedure

Keywords: pregnancy respiratory aspiration gastric contents ultrasound
the objective of this study is to evaluate the perfomance of a photorefraction device for screening ametropia in children. eligible participants will undergo multiple refractive error measurements, visual acuity and strabismus assessments during a single evaluation visit.

Conditions: Ametropia; Myopia; Refractive Error; Myopia; Astigmatism

Summary: the goal of this clinical trial is to evaluate the performance of a photorefraction screener in terms of sensibility, sensitivity and accuracy on children aged 3 to 8 y.o. the main objectives of the study are: * evaluate the performances of the device in comparison with the gold standard, i.e. a tabletop refractometer. * assess the agreement of the measures obtained with the device with those obtained with the gold standard.

participants after verification of their eligibility and informed consent, participate to a single evaluation visit during which several objective refraction measurements are performed with the investigational device, a tabletop refractometer and a comparable vision screener with and without cyclopegia. additionally far vision visual acuity, strabismus assessments and subjective refraction measurement are also performed by investigators.

Eligibility criteria:
inclusion criteria: * aged between 3-8 years when included in the study * all skin phototypes (i to vi according to the fitzpatrick classification) * wearing glasses or not * capacity to give valid consent * capacity to follow the protocol to obtain reliable measure * under french medical insurance exclusion criteria: * under myopia control solution that may have an impact on refractive error (such as: atropine, orthokeratology,..) * wearing contact lenses * ocular or systemic pathology that may have an impact on vision or may interfere with the study measures (except strabismus) * under medication that may have an impact on vision or may interfere with study measurements * known contraindication to the active substance or to one of the excipients of eye drops (mydriaticum 0.5%, skiacol 0.5%) * known risk of angle-closure glaucoma * participation to another study that may have an impact on vision or may interfere with the study measures